Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + sapanisertib
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
bevacizumab + sapanisertib is a combination therapy investigated for the treatment of recurrent glioblastoma and other advanced solid tumors. It consists of bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis, and sapanisertib (formerly MLN0128), an orally bioavailable small molecule that acts as a potent and selective inhibitor of both mTORC1 and mTORC2. By simultaneously blocking VEGF-mediated blood vessel growth and the PI3K/AKT/mTOR intracellular signaling pathway, the combination aims to overcome resistance mechanisms and provide enhanced anti-tumor activity compared to monotherapy. This combination has been primarily evaluated in Phase 1 clinical trials sponsored by the National Cancer Institute.
- Other names
- MLN0128 + bevacizumabTAK-228 + bevacizumabINK128 + bevacizumabsapanisertib + bevacizumab
02
Targets
Mechanistic target of rapamycin kinase complex 2VEGFA (Vascular endothelial growth factor A)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on bevacizumab + sapanisertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + sapanisertib.